NCT03819829 Blood Sampling of Healthy Volunteers for Immunological Research
| NCT ID | NCT03819829 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Netherlands Cancer Institute |
| Condition | Healthy Volunteers |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2019-02-05 |
| Primary Completion | 2026-12-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2019-02-05 with a primary completion date of 2026-12-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This protocol will be used to collect crucial components of the immune system from healthy volunteers for the characterization of immune cells in fresh blood. A pipeline has been set up for comprehensive immune phenotyping of both lymphoid and myeloid cells within 24 hours after blood withdrawal.
Eligibility Criteria
Inclusion Criteria: * Age above 35 years * Written informed consent * No history of cancer * No use of systemic immunosuppressive medication (eg. corticosteroids). Local use of corticosteroids (eg. topical or inhalation) is allowed. Exclusion Criteria: * Fever 14 days before blood withdrawal * Donated blood for the same program within the last 2 years * Pregnancy
Contact & Investigator
M Kok, MD
PRINCIPAL INVESTIGATOR
NKI-AvL
Frequently Asked Questions
Who can join the NCT03819829 clinical trial?
This trial is open to participants of all sexes, aged 36 Years or older, studying Healthy Volunteers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03819829 currently recruiting?
Yes, NCT03819829 is actively recruiting participants. Contact the research team at m.kok@nki.nl for enrollment information.
Where is the NCT03819829 trial being conducted?
This trial is being conducted at Amsterdam, Netherlands.
Who is sponsoring the NCT03819829 clinical trial?
NCT03819829 is sponsored by The Netherlands Cancer Institute. The principal investigator is M Kok, MD at NKI-AvL. The trial plans to enroll 50 participants.